Beardsley Robert A 4
4 · Arbutus Biopharma Corp · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
Arbutus (ABUS) Director Robert Beardsley Receives Award (78,800)
What Happened
Robert A. Beardsley, a director of Arbutus Biopharma Corp (ABUS), was granted a derivative award covering 78,800 shares on June 8, 2026. The Form 4 reports the acquisition price as $0.00 (transaction code A — grant/award). A footnote in the filing indicates the instrument is an option that is fully vested and exercisable as of the grant date.
Key Details
- Transaction date: 2026-06-08; Form 4 filed: 2026-06-10 (timely filing).
- Security: derivative (option) covering 78,800 shares; reported acquisition price $0.00.
- Footnote F1: filing references the company’s Nasdaq closing price on the grant date (value not shown here).
- Footnote F2: the option is fully vested and exercisable as of the grant date.
- Shares owned after the transaction: not specified in the provided filing excerpt.
Context
This was an award/option grant (not an open‑market purchase or sale). Because the option is fully vested and exercisable immediately, Beardsley could exercise the option per its terms, but the Form 4 shows no immediate sale. Awards to directors are commonly part of compensation or retention programs and are not by themselves a definitive signal of personal buying or selling intent.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-08+78,800→ 78,800 totalExercise: $4.24From: 2026-06-08Exp: 2036-06-08→ Common Shares (78,800 underlying)
Footnotes (2)
- [F1]Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
- [F2]The option is fully vested and exercisable as of the date of the grant.